Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

   Active, not recruiting · Phase 3 · Moderate to Severe Plaque Psoriasis

   NCT06506916 · UCB SA · 7 U.S. investigators

   $409,802research payments

2. Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

   Recruiting · Phase 3 · Breast Cancer

   NCT05950945 · Daiichi Sankyo Inc. · 6 U.S. investigators

   $408,941research payments

3. A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

   Terminated · Phase 1 · Metastatic Solid Tumors

   NCT06585488 · Beone Medicines USA, Inc. · 4 U.S. investigators

   $408,431research payments

4. Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

   Completed · Phase 1, Phase 2 · Influenza Immunization

   NCT05650554 · Sanofi Pasteur Inc. · 15 U.S. investigators

   $408,422research payments

5. Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

   Completed · Phase 3 · Relapsing Multiple Sclerosis

   NCT04410978 · Genzyme Corporation · 19 U.S. investigators

   $405,160research payments

6. A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

   Completed · Phase 2 · Venous Thromboembolism

   NCT06299111 · Regeneron Pharmaceuticals, Inc. · 6 U.S. investigators

   $404,880research payments

7. The Protrieve PROTECTOR Study

   Completed · Not applicable · Venous Thromboembolism

   NCT06495996 · Stryker Corporation · 14 U.S. investigators

   $404,553research payments

8. A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function

   Completed · Phase 1 · Liver Dysfunction

   NCT06916078 · Eli Lilly and Company · 3 U.S. investigators

   $404,005research payments

9. A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

   Recruiting · Phase 3 · Autoimmune Haemolytic Anaemia

   NCT07086976 · Genzyme Corporation · 14 U.S. investigators

   $403,870research payments

10. Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

    Completed · Phase 1, Phase 2 · Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    NCT03744468 · Beone Medicines USA, Inc. · 9 U.S. investigators

    $402,940research payments

11. A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

    Recruiting · Phase 1, Phase 2 · Multiple Myeloma

    NCT05372354 · E.r. Squibb & Sons, L.l.c. · 4 U.S. investigators

    $402,716research payments

12. A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

    Completed · Phase 2 · Head and Neck Squamous Cell Carcinoma

    NCT05909904 · Beone Medicines Ltd. · 4 U.S. investigators

    $401,720research payments

13. Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

    Recruiting · Phase 2 · Sickle Cell Disease Vaso-occlusive Crisis

    NCT06699849 · Csl Behring · 18 U.S. investigators

    $400,882research payments

14. DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

    Active, not recruiting · Phase 1 · Breast Cancer

    NCT04042701 · Daiichi Sankyo Inc. · 7 U.S. investigators

    $400,271research payments

15. A Comparison of Cyclic Manual Direct Aspiration Thrombectomy (Plunger Technique) vs. Static Manual Direct Aspiration Thrombectomy for Treatment of Acute Large Vessel Occlusion Stroke

    Recruiting · Not applicable · Acute Ischemic Stroke Patients

    NCT07231380 · Balt USA, LLC · 1 U.S. investigator

    $400,000research payments

16. A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

    Recruiting · Phase 3 · Episodic Migraine

    NCT05897320 · H. Lundbeck A S · 14 U.S. investigators

    $399,306research payments

17. (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

    Recruiting · Phase 2, Phase 3 · Indolent Systemic Mastocytosis

    NCT04910685 · Sanofi US Services Inc. · 9 U.S. investigators

    $399,273research payments

18. Paresthesia-Free Fast-Acting Subperception (FAST) Study

    Active, not recruiting · Not applicable · Chronic Pain

    NCT04618471 · Boston Scientific Corporation · 11 U.S. investigators

    $397,604research payments

19. A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age

    Completed · Phase 3 · Respiratory Syncytial Virus

    NCT06060457 · ModernaTX, Inc. · 14 U.S. investigators

    $396,330research payments

20. A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

    Active, not recruiting · Phase 2 · Colitis Ulcerative

    NCT05731128 · Sanofi US Services Inc. · 23 U.S. investigators

    $394,433research payments

21. Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma

    Recruiting · Not applicable · Adenocarcinoma of the Pancreas

    NCT07340151 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $393,547research payments

22. Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

    Completed · Phase 1 · Malignancies

    NCT03005782 · Regeneron Pharmaceuticals, Inc. · 29 U.S. investigators

    $392,128research payments

23. A Prospective Cohort Post Market Registry Evaluating Outcomes of Bridge-Enhanced ACL Restoration (BEAR®)

    Active, not recruiting · Anterior Cruciate Ligament Injuries

    NCT05398341 · Miach Orthopaedics, Inc. · 7 U.S. investigators

    $391,854research payments

24. Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

    Active, not recruiting · Phase 4 · Pulmonary Embolism

    NCT04790370 · Boston Scientific Corporation · 27 U.S. investigators

    $391,403research payments

25. Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

    Completed · Phase 3 · Influenza Immunization

    NCT05513053 · Sanofi Pasteur Inc. · 17 U.S. investigators

    $390,992research payments

26. Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

    Enrolling by invitation · Phase 2, Phase 3 · Immunoglobulin A Nephropathy

    NCT05248659 · Otsuka Pharmaceutical Development & Commercialization, Inc. · 11 U.S. investigators

    $390,080research payments

27. A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function

    Completed · Phase 1 · Renal Insufficiency

    NCT07137689 · Eli Lilly and Company · 4 U.S. investigators

    $385,703research payments

28. A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

    Completed · Phase 2 · Zika Virus

    NCT04917861 · ModernaTX, Inc. · 7 U.S. investigators

    $384,610research payments

29. A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese Participants

    Completed · Phase 1 · Healthy Volunteer

    NCT06722417 · AbbVie Inc. · 1 U.S. investigator

    $384,552research payments

30. Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

    Active, not recruiting · Migraine

    NCT06543914 · AbbVie Inc. · 12 U.S. investigators

    $384,402research payments

31. The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM)

    Completed · Not applicable · Subdural Hematoma, Chronic

    NCT04410146 · Balt USA, LLC · 20 U.S. investigators

    $382,602research payments

32. LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)

    Active, not recruiting · Phase 2 · Paraganglioma

    NCT03946527 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $382,480research payments

33. A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

    Recruiting · Phase 4 · SARS-CoV-2

    NCT06585241 · ModernaTX, Inc. · 2 U.S. investigators

    $381,615research payments

34. Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

    Terminated · Phase 1 · Advanced NSCLC

    NCT04982224 · Regeneron Pharmaceuticals, Inc. · 12 U.S. investigators

    $380,885research payments

35. Retrospective Analysis of Prismaflex HF20 Set Versus ppCRRT Registry

    Completed · Acute Renal Failure (ARF)

    NCT06633029 · Vantive US Healthcare LLC · 6 U.S. investigators

    $380,401research payments

36. A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

    Active, not recruiting · Phase 3 · Atopic Dermatitis

    NCT05559359 · Eli Lilly and Company · 20 U.S. investigators

    $380,203research payments

37. Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

    Active, not recruiting · Phase 3 · Non-small Cell Lung Cancer

    NCT04656652 · Daiichi Sankyo Inc. · 17 U.S. investigators

    $379,206research payments

38. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    Recruiting · Phase 2 · Breast Neoplasms

    NCT01042379 · Regeneron Pharmaceuticals, Inc. · 20 U.S. investigators

    $379,149research payments

39. Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor

    Completed · Phase 2 · Upper Limb Essential Tremor (UL ET)

    NCT05216250 · AbbVie Inc. · 55 U.S. investigators

    $379,027research payments

40. Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

    Completed · Phase 1 · Non-Hodgkin Lymphoma

    NCT02290951 · Regeneron Pharmaceuticals, Inc. · 2 U.S. investigators

    $377,960research payments

41. A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

    Active, not recruiting · Phase 3 · Medullary Thyroid Cancer

    NCT04211337 · Eli Lilly and Company · 12 U.S. investigators

    $376,756research payments

42. Expanded Indications in the Pediatric BONEBRIDGE Population

    Active, not recruiting · Not applicable · Hearing Loss, Conductive

    NCT05615649 · Med-el Corporation · 5 U.S. investigators

    $376,315research payments

43. Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

    Recruiting · Phase 2 · Basal Cell Carcinoma

    NCT06624475 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $374,631research payments

44. Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

    Completed · Phase 1 · Solid Tumor, Adult

    NCT03905148 · Beigene Aus Pty Ltd · 3 U.S. investigators

    $373,605research payments

45. Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

    Terminated · Phase 1, Phase 2 · Neoplasm

    NCT05450562 · Sanofi US Services Inc. · 4 U.S. investigators

    $372,144research payments

46. Fixed-Dose Trial in Early Parkinson's Disease (PD)

    Completed · Phase 3 · Parkinson Disease

    NCT04201093 · AbbVie Inc. · 30 U.S. investigators

    $371,849research payments

47. Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data From Electronic Health Records (EHRs) in the United States (Project Searchlight)

    Completed · Not applicable · Gaucher Disease

    NCT05908656 · Sanofi US Services Inc. · 3 U.S. investigators

    $369,852research payments

48. HEAL-IST IDE Trial

    Active, not recruiting · Not applicable · Inappropriate Sinus Tachycardia

    NCT05280093 · Atricure, Inc. · 23 U.S. investigators

    $366,679research payments

49. PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection

    Active, not recruiting · Not applicable · Acute Aortic Dissection

    NCT05174767 · Artivion, Inc. · 17 U.S. investigators

    $365,320research payments

50. A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

    Recruiting · Phase 3 · Type 1 Diabetes Mellitus

    NCT07088068 · Sanofi US Services Inc. · 11 U.S. investigators

    $364,787research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.